Many attempts have been made to outline the predictive value of KRAS mutations in NSCLC patients treated with standard chemotherapy [110,111,112,113], targeted therapies [114,115] and immune check point inhibition [116]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.